Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00753649
First received: September 12, 2008
Last updated: October 6, 2016
Last verified: February 2014
  Purpose
This study will evaluate GSK Biologicals' DTPa-HBV-IPV/Hib vaccine given as a three-dose primary vaccination course at 2, 4 and 6 months of age, in terms of safety and immunogenicity in different population of infants residing in Canada.

Condition Intervention Phase
Hepatitis B
Tetanus
Poliomyelitis
Diphtheria
Haemophilus Influenzae Type b
Acellular Pertussis
Biological: Infanrix™ hexa
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa Vaccine in Healthy Infants

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (Anti-PRP) [ Time Frame: One month after (POST) Dose 3. ] [ Designated as safety issue: No ]
    A seroprotected subject was a subject whose anti-PRP antibody concentration was greater or equal to (≥) 0.15 microgram per milliliter (µg/mL).


Secondary Outcome Measures:
  • Number of Subjects With Anti-PRP Antibody Concentrations ≥1µg/mL [ Time Frame: One month after (POST) Dose 3. ] [ Designated as safety issue: No ]
    For this assay, 1 μg/mL was considered as the seropositivity cut-off.

  • Anti-PRP Antibody Concentrations [ Time Frame: One month after (POST) Dose 3. ] [ Designated as safety issue: No ]
    Anti-PRP antibody concentrations were presented as Geometric mean Concentrations (GMC), expressed as micrograms per milliliter (μg/mL).

  • Number of Seroprotected Subjects Against Hepatitis B (Anti-HBs) [ Time Frame: One month after (POST) Dose 3. ] [ Designated as safety issue: No ]
    A seroprotected subject was a subject with anti-HBs antibody concentrations ≥ 10 milli-International Units ler milliliter (mIU/mL). A decrease in the specificity of the anti-HB ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis. Some of the available blood samples initially tested with ELISA were re-tested using the new assay, CLIA.

  • Number of Subjects With Anti-HBs Antibody Concentrations ≥100 mIU/mL [ Time Frame: One month after (POST) Dose 3. ] [ Designated as safety issue: No ]
    The testing was done using the Enzyme-Linked Immunosorbent assay (ELISA) assay.

  • Anti-HBs Antibody Concentrations [ Time Frame: One month after (POST) Dose 3. ] [ Designated as safety issue: No ]
    Anti-HBs antibody concentrations were assessed by Enzyme-Linked Immunosorbent assay (ELISA) and expressed as geometric mean concentrations (GMCs).

  • Number of Subjects With Unsolicited Adverse Events (AEs) [ Time Frame: During the 31 day (Days 0-30) post vaccination ] [ Designated as safety issue: No ]
    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

  • Number of Subjects With Serious Adverse Events (SAEs) [ Time Frame: During the entire study period up to Last subject last visit on 03/12/2013 ] [ Designated as safety issue: No ]
    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.


Enrollment: 224
Study Start Date: September 2008
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Aboriginal infants group Biological: Infanrix™ hexa
Intramuscular, three doses
Other Name: DTPa-HBV-IPV/Hib
Active Comparator: Other Non-Aboriginal infants Biological: Infanrix™ hexa
Intramuscular, three doses
Other Name: DTPa-HBV-IPV/Hib

Detailed Description:
This protocol posting has been updated following Protocol amendment 1 (19-MAY-2010).
  Eligibility

Ages Eligible for Study:   6 Weeks to 12 Weeks   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
  • Born after a gestation period of 36 to 42 weeks inclusive.
  • Healthy subjects as established by medical history before entering into the study.
  • Written informed consent obtained from the parent or guardian of the subject.

Exclusion Criteria:

  • Use of any investigational or non-registered product within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs from birth until first primary vaccination dose..
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Major congenital defects or serious chronic illness.
  • Evidence of previous or intercurrent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and/or Hib vaccination or disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
  • The following condition is temporary or self limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:
  • Current febrile illness or axillary temperature of ≥ 37.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00753649

Locations
Canada, Alberta
GSK Investigational Site
Edmonton, Alberta, Canada, T5M 3Z7
Canada, British Columbia
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 4H4
Canada, Nova Scotia
GSK Investigational Site
Truro, Nova Scotia, Canada, B2N 1L2
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00753649     History of Changes
Other Study ID Numbers: 103506 
Study First Received: September 12, 2008
Results First Received: October 6, 2016
Last Updated: October 6, 2016
Health Authority: Canada: Health Canada

Keywords provided by GlaxoSmithKline:
Infant
First nation
Aboriginal
Canada

Additional relevant MeSH terms:
Hepatitis B
Diphtheria
Poliomyelitis
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Hepatitis
Liver Diseases
Digestive System Diseases
Corynebacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Myelitis
Central Nervous System Infections
Central Nervous System Diseases
Nervous System Diseases
Spinal Cord Diseases
Neuromuscular Diseases

ClinicalTrials.gov processed this record on December 07, 2016